Health Care Supplies

Avanos Medical

Avanos Medical released FY2026 Q1 earnings on May 5 (EST), actual revenue USD 182.2 M (forecast USD 170 M), actual EPS USD 0.1096

Avanos Medical released FY2025 earnings on February 24 Pre-Market EST, actual revenue USD 701.2 M (forecast USD 695 M), actual EPS USD -1.5745 (forecast USD 0.4)

Avanos Medical released FY2025 Q4 earnings on February 24 Pre-Market (EST), actual revenue USD 180.9 M (forecast USD 174.7 M), actual EPS USD -0.03

Avanos Medical to Release FY2025 Q4 Earnings on February 24, 2026, Pre-Market EST; Forecasted Revenue USD 174.7 M

Avanos Medical CEO Shares Growth Strategies at JPM Healthcare Conference

Avanos Medical released FY2025 9 Months Earnings on November 5 Pre-Market EST, with actual revenue of USD 520.3 M and EPS of USD -1.5501

Avanos Medical released FY2025 Q3 earnings on November 5 Pre-Market EST, actual revenue USD 177.8 M (forecast USD 164.5 M), actual EPS USD -0.0301

Avanos Medical to Release FY2025 Q3 Earnings on November 5, Pre-Market EST; Forecast Revenue USD 164.5 M

Avanos Medical released FY2025 Q2 earnings on August 5 Pre-Market (EST), actual revenue USD 175 M (forecast USD 165.5 M), actual EPS USD -1.66

Avanos Medical released FY2025 Semi-Annual earnings on August 5 Pre-Market (EST), actual revenue USD 342.5 M, actual EPS USD -1.52

Avanos Medical to Release FY2025 Q2 Earnings on August 5, Pre-Market EST, Forecast Revenue USD 165.5 M

D.E. Shaw Increased Holdings of Avanos Medical in Q4

Avanos Medical released FY2025 Q1 earnings on May 6 Pre-Market EST, actual revenue USD 167.5 M (forecast USD 161.75 M), actual EPS USD 0.14

Avanos Medical Reports Q1 Financial Results

Avanos Medical to Report Quarterly Earnings, Expected EPS at $0.18

Avanos Medical Inc projects Q1 2025 earnings of 18 cents

Avanos Medical Submits Interim CFO's Beneficial Ownership Statement

Avanos Medical to Release FY2025 Q1 Earnings on May 6 Pre-Market EST, Forecast Revenue USD 161.75 M

Avanos Medical Takes Over Sales and Distribution of MIC-KEY Products in the UK

Avanos Medical Reports Quarterly EPS Exceeding Expectations and Updates 2025 Guidance

Micware

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

GCL Global

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Jupiter Neurosciences

Linkage Global

Capstone

BiomX

AVNS

Two health care stocks, Avanos Medical Inc (AVNS) and Agilon Health Inc (AGL), are showing signs of being overbought, with RSI values of 87.8 and 86.6, respectively. AVNS has surged 127% over the past six months, while AGL has skyrocketed 212% in the last month. Both companies reported better-than-expected earnings and raised sales guidance, but their high RSI indicates potential price corrections ahead.

benzinga_article

agilon health

Health Care Select Sector SPDR

VG Health

iShares US Healthcare Providers

Top 2 Health Care Stocks That May Plunge This Month

Earnings Watch

Avanos Medical | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 182.2 M

APLS

CERS

LABU

Three healthcare stocks, Avanos Medical (AVNS), Apellis Pharmaceuticals (APLS), and Cerus Corp (CERS), are showing signs of being overbought, with RSI values of 90, 86.8, and 86 respectively. AVNS has gained 78% recently due to a going-private deal, APLS surged 100% following an acquisition announcement by Biogen, and CERS reported strong Q1 results, raising its sales guidance. Investors should be cautious as these stocks may face a downturn.

Apellis Pharma

Cerus

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Biogen

Top 3 Health Care Stocks That May Collapse This Month

SLNO

OMEX

Halper Sadeh LLC is investigating Whitestone REIT (WSR), Soleno Therapeutics (SLNO), Odyssey Marine Exploration (OMEX), and Avanos Medical (AVNS) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. Shareholders are encouraged to contact the firm for legal rights and options regarding the proposed transactions, which include sales and mergers at specified prices per share.

prnewswire

Whitestone Reit -B

Soleno Therapeutics

Odyssey Marine

ARES Management LP

Neurocrine Biosciences

ARES MANAGEMENT CORPORATION 6.75% MAN PFD CONV SER B

11:43 ETAre WSR, SLNO, OMEX, AVNS Obtaining Fair Deals for their Shareholders?

GRTX

GSAT

Class Action Attorney Juan Monteverde is investigating mergers involving Leggett & Platt (LEG), Avanos Medical (AVNS), Galera Therapeutics (GRTX), and Globalstar (GSAT). Leggett & Platt shareholders will receive shares of Somnigroup, Avanos shareholders will get $25 per share in cash, Galera shareholders will own 1.8% of the merged entity with Obsidian, and Globalstar shareholders can choose between cash or Amazon stock capped at $90 per share. The firm has a successful track record in recovering funds for shareholders.

Galera Therapeutics

Globalstar

Leggett & Platt

Somnigroup

Amazon

13:27 ET$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--LEG, AVNS, GRTX, and GSAT

TVTX

RYLPF

HOTH

REPL

This week's biotech news highlights significant regulatory approvals and rejections, including FDA clearance for Royal Philips' AI-powered Spectral CT and full approval for Travere's FILSPARI for FSGS. Nxera Pharma's QUVIVIQ received Taiwan approval for insomnia, while Replimune faced a second FDA rejection for RP1 in melanoma. Notable acquisitions include Stereotaxis acquiring Robocath and American Industrial Partners' $1.27 billion deal for Avanos Medical. The landscape also features collaborations, such as Sana's partnership with Mayo Clinic for SC451.

rttnews

Travere Therapeutics

Koninklijke Philips N.V.

Hoth Therapeutics

Replimune

Koninklijke Philips Elect

Sosei Group Corporation

Regeneron Pharma

Sanofi

Stereotaxis

Mesoblast

Mesoblast Limited

Weekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials

RVMD

Two health care stocks, Avanos Medical Inc (NYSE:AVNS) and Revolution Medicines Inc (NASDAQ:RVMD), are identified as potentially overbought, with high RSI values indicating a risk of poor short-term performance. Avanos Medical, recently agreeing to be acquired for $1.272 billion, has an RSI of 91.2 and saw a 0.2% drop in stock price. Revolution Medicines, which raised $2 billion through offerings, has an RSI of 83.5 and experienced a 2.1% decline in stock price. Investors should be cautious with these stocks in Q2.

Fidelity

Revolution Medicines

Direxion S&P Biotech Bear 3X

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Top 2 Health Care Stocks That May Fall Off A Cliff In Q2

Avanos Medical (NYSE:AVNS) experienced a significant increase in trading volume, with 1,089,603 shares traded, up 21% from the previous session. The stock is currently priced at $24.6050. The company has agreed to be acquired by American Industrial Partners for $25.00 per share, representing a 72% premium. Despite positive earnings reports, legal investigations regarding the sale may pose risks. Analysts have mixed ratings, with a consensus rating of "Reduce." Institutional investors have shown increased interest in the stock, reflecting a positive outlook on its fundamentals.

Market Beat

Avanos Medical (NYSE:AVNS) Sees Strong Trading Volume  - Here's What Happened

KEEL

IONQ

CRDO

JBLU

QBTS

APLD

TWST

Avanos Medical(AVNS) rose 69.51%, with a trading turnover 587.6 Million USD, and a year-to-date rose 119.3%. Travere Therapeutics(TVTX) rose 37.23%, with a trading turnover 621.9 Million USD, and a year-to-date rose 10.3%. Bloom Energy(BE) rose 23.98%, with a trading turnover 5.3 Billion USD, and a year-to-date rose 152.1%.

Avanos Medical(AVNS.US)